Skip to main content

Table 2 Estimated NIS-LL at Months 6, 12, and 18, according to baseline neurologic severity and treatment group

From: Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Baseline NIS-LL

Treatment group

Month 6

Month 12

Month 18

5

T-T

5.6 (0.5)

6.3 (0.6)

6.9 (0.7)

 

P-T

6.4 (0.5)

8.1 (0.6)

9.8 (0.8)

15

T-T

16.7 (0.5)

18.0 (0.6)

19.2 (0.8)

 

P-T

17.6 (0.5)

19.8 (0.6)

22.0 (0.7)

25

T-T

27.9 (0.6)

29.7 (0.7)

31.5 (0.9)

 

P-T

28.7 (0.6)

31.5 (0.7)

34.3 (0.9)

  1. Data are shown as mean (standard error)
  2. NIS-LL Neuropathy Impairment Score − Lower Limbs; P-T placebo-to-tafamidis; T-T tafamidis-to-tafamidis